<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875004</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633325</org_study_id>
    <secondary_id>CLCC-PLATON</secondary_id>
    <secondary_id>CLCC-VA-2007/21</secondary_id>
    <secondary_id>CLCC-AFSSAPS-A70755-52</secondary_id>
    <secondary_id>INCA-RECF0639</secondary_id>
    <secondary_id>EUDRACT-2007-003615-31</secondary_id>
    <secondary_id>ROCHE-CLCC-PLATON</secondary_id>
    <nct_id>NCT00875004</nct_id>
  </id_info>
  <brief_title>Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors</brief_title>
  <official_title>Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or
      reduce side effects in patients undergoing chemotherapy for solid tumors.

      PURPOSE: This clinical trial is studying how well epoetin beta works in patients undergoing
      chemotherapy for solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Identify factors predictive of treatment failure in patients with solid tumors treated
           with epoetin beta while undergoing chemotherapy.

      Secondary

        -  Evaluate the impact of achieving target hemoglobin levels (i.e., hemoglobin &gt; 11 g/dL)
           after 8 weeks of treatment with epoetin beta.

        -  Evaluate changes in hemoglobin levels from baseline to after 8 weeks of treatment with
           epoetin beta.

        -  Evaluate the tolerability of epoetin beta in these patients.

        -  Evaluate the quality of life of these patients.

      OUTLINE: This is a multicenter study.

      Patients receive epoetin beta subcutaneously once a week for ≥ 8 weeks in the absence of
      disease progression or unacceptable toxicity.

      Patients complete a quality-of-life questionnaire (FACT-An) at baseline and after 8 weeks of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure (changes in hemoglobin levels)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Anemia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of solid tumor

          -  Hemoglobin 9-11 g/dL

          -  Planning to receive epoetin beta for ≥ 8 weeks while undergoing chemotherapy for
             cancer

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Not pregnant or nursing

          -  Not incarcerated or under guardianship

          -  No psychological, familial, social, or geographical reason that would preclude study
             follow-up

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 6 months since prior epoetin

          -  No concurrent chemoradiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien Pouessel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Pouessel, MD</last_name>
      <phone>33-4-6761-3545</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>December 13, 2009</last_update_submitted>
  <last_update_submitted_qc>December 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <keyword>anemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

